García Pérez de Sevilla, GuillermoBlanco Velasco, ÁngelaSanz Santiago, VerónicaMorales Tirado, AnaLópez Neyra, AlejandroManuel, Cristina deRuiz Valbuena, MartaPérez Ruiz, Margarita2025-11-152025-11-152025García-Pérez-de-Sevilla, G., Blanco Velasco, Á., Yvert, T., Sanz-Santiago, V., Tirado, A. M., López Neyra, A., De Manuel, C., Ruiz Valbuena, M., & Pérez-Ruiz, M. (2025). Respiratory muscle function in children and adolescents with cystic fibrosis in the era of cftr modulator therapies. Children, 12(7), 878. https://doi.org/10.3390/children120708782227-9067https://hdl.handle.net/11268/16471The objective of this study was to analyze respiratory muscle function in children and adolescents with cystic fibrosis (CF) treated with Elexacaftor/Tezacaftor/Ivacaftor (ETI) compared to healthy individuals, based on the hypothesis that CFTR modulators may improve respiratory muscle strength. Children and adolescents with CF treated with ETI showed respiratory muscle strength comparable to that of healthy controls. Despite differences in lifestyle factors, these findings may reflect a positive impact of CFTR modulators on respiratory muscle function, although further longitudinal and controlled studies are needed.engAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/journal article10.3390/children12070878open accessCiencias médicasPediatríaAparato respiratorioGoal 3: Ensure healthy lives and promote well-being for all at all agesGoal 9: Build resilient infrastructure, promote sustainable industrialization and foster innovationGoal 10: Reduce inequality within and among countries